Ionis Pharmaceuticals, Inc. (IONS) Financial Statements (2024 and earlier)

Company Profile

Business Address 2855 GAZELLE COURT
CARLSBAD, CA 92010
State of Incorp. CA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,385,3882,346,7811,986,8691,981,6632,021,8272,052,393
Cash and cash equivalents424,790309,031276,472314,993521,917542,513
Short-term investments1,960,5982,037,7501,710,3971,666,6701,499,9101,509,880
Inventory, net of allowances, customer advances and progress billings25,53822,20022,03320,64519,81124,032
Inventory25,53822,20022,03320,64519,81124,032
Contract with customer, asset, after allowance for credit loss27,95613,91425,5386,6456,75126,122
Other current assets177,872159,724168,254143,173142,759150,577
Total current assets:2,616,7542,542,6192,202,6942,152,1262,191,1482,253,124
Noncurrent Assets
Operating lease, right-of-use asset176,718179,148181,544   
Property, plant and equipment91,63485,15874,294180,806177,015177,724
Intangible assets, net (including goodwill)    29,60529,05429,295
Intangible assets, net (excluding goodwill)    29,60529,05429,295
Other noncurrent assets86,02578,29675,34459,43458,91658,949
Total noncurrent assets:354,377342,602331,182269,845264,985265,968
TOTAL ASSETS:2,971,1312,885,2212,533,8762,421,9712,456,1332,519,092
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities128,766123,201158,022178,973169,686132,807
Taxes payable1614901
Employee-related liabilities30,41024,98516,525
Accounts payable24,02110,49917,92120,54510,35116,125
Accrued liabilities104,745112,702140,101128,002134,33699,256
Deferred revenue96,25292,33590,57799,51193,39391,437
Debt   151   
Other liabilities8,9038,2397,535   
Other undisclosed current liabilities54,05435,44655,2764,9704,7324,206
Total current liabilities:287,975259,221311,561283,454267,811228,450
Noncurrent Liabilities
Long-term debt and lease obligation  8,811 58,97859,22259,462
Long-term debt, excluding current maturities  8,811 58,97859,22259,462
Liabilities, other than long-term debt445,854457,460473,835294,656315,196333,138
Deferred revenue254,398272,973287,768294,656315,196333,138
Other liabilities16,4367,4877,126   
Operating lease, liability175,020177,000178,941   
Other undisclosed noncurrent liabilities1,809,0011,673,1591,175,5931,190,5221,189,1781,188,468
Total noncurrent liabilities:2,254,8552,139,4301,649,4281,544,1561,563,5961,581,068
Total liabilities:2,542,8302,398,6511,960,9891,827,6101,831,4071,809,518
Equity
Equity, attributable to parent428,301486,570572,887594,361624,726709,574
Common stock143143142142142142
Additional paid in capital2,118,3092,089,3582,059,8502,034,5542,008,7941,983,078
Accumulated other comprehensive loss(50,913)(48,983)(57,480)(63,140)(54,007)(48,578)
Accumulated deficit(1,639,238)(1,553,948)(1,429,625)(1,377,195)(1,330,203)(1,225,068)
Total equity:428,301486,570572,887594,361624,726709,574
TOTAL LIABILITIES AND EQUITY:2,971,1312,885,2212,533,8762,421,9712,456,1332,519,092

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues188,411130,524151,889159,767133,791141,919
Cost of revenue(232,464)(198,104)(460,605)(184,505)(185,503)(164,067)
Gross profit:(44,053)(67,580)(308,716)(24,738)(51,712)(22,148)
Operating expenses(46,142)(46,568)100,697(34,416)(33,802)(35,356)
Operating loss:(90,195)(114,148)(208,019)(59,154)(85,514)(57,504)
Nonoperating income (expense)32,69318,32815,81614,584(15,231)(4,445)
Investment income, nonoperating21,51018,09815,1679,871(2,934)(4,632)
Other nonoperating income (expense)11,1832306494,713(12,297)187
Interest and debt expense(2,291)(1,608)(1,731)(2,139)(2,130)(2,122)
Loss from continuing operations before equity method investments, income taxes:(59,793)(97,428)(193,934)(46,709)(102,875)(64,071)
Other undisclosed income (loss) from continuing operations before income taxes(17,655)(15,515)149,604   
Loss from continuing operations before income taxes:(77,448)(112,943)(44,330)(46,709)(102,875)(64,071)
Income tax expense(7,842)(11,380)(8,100)(283)(2,260)(1,094)
Loss from continuing operations:(85,290)(124,323)(52,430)(46,992)(105,135)(65,165)
Loss before gain (loss) on sale of properties:(46,992)(105,135)(65,165)
Net loss available to common stockholders, diluted:(85,290)(124,323)(52,430)(46,992)(105,135)(65,165)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(85,290)(124,323)(52,430)(46,992)(105,135)(65,165)
Other undisclosed comprehensive loss   (24,812)   
Comprehensive loss:(85,290)(124,323)(77,242)(46,992)(105,135)(65,165)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,930)8,49730,472(9,133)(5,429)(15,910)
Comprehensive loss, net of tax, attributable to parent:(87,220)(115,826)(46,770)(56,125)(110,564)(81,075)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: